This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by ...

Analyst Chris Shibutani from Goldman Sachs reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report) and keeping the price ...

In a report released yesterday, Carter Gould from Barclays maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), with ...

Shares jumped 6% in premarket trading after the Food and Drug Administration approved a treatment for [schizophrenia patients]( ...

Bristol-Myers Squibb won Food and Drug Administration approval late Thursday for its novel schizophrenia drug, Cobenfy. BMY ...

While not a mind-blowing move, it is good to see that the Bristol-Myers Squibb Company (NYSE:BMY) share price has gained 22% in the last three months. But that doesn't help the fact that the three ...

Bristol Myers Squibb (BMY) ended the recent trading session at $48.59, demonstrating a -1.4% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily ...

8 analysts have expressed a variety of opinions on Bristol-Myers Squibb BMY over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed ...